All In Biotech

Drug Trial Radar · NCT07550387

A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia

A Randomized, Double-Blind, Active-Controlled and Placebo-Controlled Phase 2b Clinical Study to Evaluate the Efficacy and Safety of HS-10380 in Chinese Adult Patients With Acute Schizophrenia

Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 363 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

363

Actual

Start

May 23, 2024

Primary completion

Jan 2, 2026

Study completion Jan 19, 2026

Sponsor

Sponsor type
Industry
First posted
Apr 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2b, randomized, double-blind, parallel-group, active-controlled and placebo-controlled, multicenter inpatient study to examine the efficacy and safety of HS-10380 in adult Participants who are acutely psychotic with a Diagnostic and Statistical Manual Fifth Edition (DSM-5) diagnosis of schizophrenia. The primary objective of the study is to assess the efficacy of HS-10380 versus placebo in reducing Positive and Negative Syndrome Scale (PANSS) total scores in adult inpatients with a DSM-5 diagnosis of schizophrenia. The secondary objectives of the study are to evaluate the response rate, improvement in disease severity and symptoms, safety and tolerability, and pharmacokinetics.

Conditions

  • SCHIZOPHRENIA 1 (Disorder)

Interventions

  • HS-10380 Low DoseDrug

    W1:dose titration; W 2-3 dose adjust to optimal level;Week 4-6:stable dose

  • HS-10380 Medium doseDrug

    W1: dose titration; W 2-3: dose adjust to optimal level; Week 4-6: stable dose

  • HS-10380 High DoseDrug

    W1: dose titration; W 2-3: dose adjust to optimal level; Week 4-6: stable dose

  • AripiprazoleDrug

    W1: dose titration; W 2-3: dose adjust to optimal level; Week 4-6: stable dose

  • PlaceboDrug

    W1: dose titration; W 2-3: dose adjust to optimal level; Week 4-6: stable dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 (Day 42)Time frame: Baseline and Week 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Mental Health Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.